Literature DB >> 19264517

Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation.

Hana Bruchova1, Donghoon Yoon, Archana M Agarwal, Sabina Swierczek, Josef T Prchal.   

Abstract

Polycythemia vera (PV) is an acquired myeloproliferative clonal disorder, characterized by augmented erythropoiesis. To better define PV pathogenesis, we performed an in vitro erythroid expansion from peripheral blood mononuclear cells of controls and PV patients and evaluated the cells for proliferation, apoptosis, erythroid differentiation, and morphology at the defined time points. PV erythroid progenitors exhibited increased proliferation at days 9-14 and accelerated maturation at days 7-14, with a larger S-phase population (40%) than controls (20%) at day 11; however, the proportion of apoptotic cells was comparable to controls. Previously, we have identified PV-specific dysregulation of several microRNAs (i.e. miR-150, 451, 222, 155, 378). We had analyzed expression profiles of selected target genes of these microRNAs based on in silico prediction and their known function pertinent to the observed PV-specific erythropoiesis differences. p27, cMYB and EPOR showed differential expression in PV erythroid progenitors at the specific stages of erythroid differentiation. In this study, we identified accelerated maturation and hyper-proliferation at early stages of PV erythropoiesis. We speculate that aberrant expression of p27, c-MYB, and EPOR may contribute to these abnormal features in PV erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264517      PMCID: PMC2693444          DOI: 10.1016/j.bcmd.2009.02.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  38 in total

1.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells.

Authors:  Marie-Catherine Giarratana; Ladan Kobari; Hélène Lapillonne; David Chalmers; Laurent Kiger; Thérèse Cynober; Michael C Marden; Henri Wajcman; Luc Douay
Journal:  Nat Biotechnol       Date:  2004-12-26       Impact factor: 54.908

2.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 3.  Polycythemia vera and other primary polycythemias.

Authors:  Josef T Prchal
Journal:  Curr Opin Hematol       Date:  2005-03       Impact factor: 3.284

Review 4.  Transcription factor GATA-1 and erythroid development.

Authors:  M C Simon
Journal:  Proc Soc Exp Biol Med       Date:  1993-02

5.  Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines.

Authors:  M Silva; A Benito; C Sanz; F Prosper; D Ekhterae; G Nuñez; J L Fernandez-Luna
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

6.  Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.

Authors:  M Socolovsky; A E Fallon; S Wang; C Brugnara; H F Lodish
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

7.  In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.

Authors:  L Y Shih; C T Lee; L C See; Y C Ou; P Dunn; P N Wang; M C Kuo; J H Wu
Journal:  Eur J Clin Invest       Date:  1998-07       Impact factor: 4.686

8.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor.

Authors:  H Wu; X Liu; R Jaenisch; H F Lodish
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

9.  Dynamics of GATA transcription factor expression during erythroid differentiation.

Authors:  M Leonard; M Brice; J D Engel; T Papayannopoulou
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

10.  Functional analysis of the c-myb proto-oncogene.

Authors:  H H Lin; D C Sternfeld; S G Shinpock; R A Popp; M L Mucenski
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

View more
  9 in total

1.  Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.

Authors:  Sabina I Swierczek; Donghoon Yoon; Christine Bellanné-Chantelot; Soo Jin Kim; Cécile Saint-Martin; Francois Delhommeau; Albert Najman; Josef T Prchal
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

2.  The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients.

Authors:  Lilian Varricchio; Elena Masselli; Elena Alfani; Angela Battistini; Giovanni Migliaccio; Alessandro Maria Vannucchi; Wenyong Zhang; Damiano Rondelli; James Godbold; Barbara Ghinassi; Carolyn Whitsett; Ronald Hoffman; Anna Rita Migliaccio
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

3.  Isolation and characterization of microRNAs of human mature erythrocytes.

Authors:  Carolyn Sangokoya; Gregory LaMonte; Jen-Tsan Chi
Journal:  Methods Mol Biol       Date:  2010

4.  Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera.

Authors:  Todd Hricik; Giulia Federici; Ann Zeuner; Giuliana Alimena; Agostino Tafuri; Valentina Tirelli; Lilian Varricchio; Francesca Masiello; Fiorella Ciaffoni; Stefania Vaglio; Emanuel F Petricoin; Gabriella Girelli; Ross L Levine; Anna Rita F Migliaccio
Journal:  Am J Hematol       Date:  2013-07-03       Impact factor: 10.047

Review 5.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control.

Authors:  H Jäkel; C Weinl; L Hengst
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

7.  Expression patterns of microRNAs associated with CML phases and their disease related targets.

Authors:  Kateřina Machová Poláková; Tereza Lopotová; Hana Klamová; Pavel Burda; Marek Trněný; Tomáš Stopka; Jana Moravcová
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

8.  Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance.

Authors:  Saeid Shahrabi; Ali Ehsanpour; Somayyeh Heidary; Mohammad Shahjahani; Masumeh Maleki Behzad
Journal:  Oncol Rev       Date:  2018-10-02

9.  JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.

Authors:  Alexandra Wolf; René Eulenfeld; Karoline Gäbler; Catherine Rolvering; Serge Haan; Iris Behrmann; Bernd Denecke; Claude Haan; Fred Schaper
Journal:  JAKSTAT       Date:  2013-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.